Be the first to like this.

1 comment(s). Last comment by probability 2020-11-21 16:39

probability

14,500 posts

Posted by probability > 2020-11-21 16:39 | Report Abuse

Here's the Coronavirus Vaccine Maker That's Most Likely to Blow Past Pfizer and Moderna

https://www.fool.com/investing/2020/11/20/coronavirus-vaccine-maker-past-pfizer-moderna/

Nov 20, 2020

J&J's coronavirus vaccine candidate, though, requires only one dose.

This could give J&J a significant competitive advantage over its rivals. A single-dose vaccine would have a lower cost than a two-dose regimen. People would also be more likely to want to receive a vaccine that they only have to take once.

Johnson & Johnson also won't have the ultra-cold storage requirements that Pfizer's vaccine has. Its COVID-19 vaccine can remain stable for up to two years at around minus four degrees Fahrenheit and for up to three months at temperatures between around 35 degrees and 46 degrees Fahrenheit.

In addition, J&J beats Moderna when it comes to production capacity. Moderna has stated that it will be able to make around 500 million doses of mRNA-1273 next year, although the biotech says that it could "possibly" up that to 1 billion doses. J&J is on track to produce more than 1 billion doses per year.

Post a Comment
Market Buzz